董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Donald G. Fell | 男 | Independent Director | 80 | 30.78万美元 | 36.92 | 2026-10-28 |
| Mayur Doshi | 男 | Independent Director | 64 | 38.44万美元 | 55.84 | 2026-10-28 |
| Narasimhan Mani | 男 | Director, Co-Chief Executive Officer, President and Interim Chief Financial Officer | 51 | 126.52万美元 | 294.55 | 2026-10-28 |
| Shankar Hariharan | 男 | Co-Chief Executive Officer and Executive Chairman of the Board | 69 | 116.52万美元 | 389.04 | 2026-10-28 |
| Subbarao Jayanthi | 男 | Independent Director | 55 | 18.44万美元 | 19.99 | 2026-10-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Narasimhan Mani | 男 | Director, Co-Chief Executive Officer, President and Interim Chief Financial Officer | 51 | 126.52万美元 | 294.55 | 2026-10-28 |
| Shankar Hariharan | 男 | Co-Chief Executive Officer and Executive Chairman of the Board | 69 | 116.52万美元 | 389.04 | 2026-10-28 |
董事简历
中英对照 | 中文 | 英文- Donald G. Fell
-
Donald G. Fell自2014年1月起担任公司独立董事。Fell先生还曾担任SPAC的董事。Kernel Group Holdings, Inc.（纳斯达克股票代码：KRNL）自2022年12月起担任SPAC的董事。OceanTech Acquisitions I Corp.丨OTEC（纳斯达克股票代码：TERM3）自2023年3月起担任董事，以及SPAC的Integrated Wellness Acquisition Corp（纽约证券交易所股票代码：WEL）的董事，自2024年2月起担任。Fell先生于2021年6月至2023年2月完成初始业务合并期间，曾担任SPAC旗下Aesther Healthcare Acquisition Corp.（n/k/a Ocean Biomedical, Inc.（纳斯达克股票代码：TERM1））的董事。Fell先生于2023年6月至2024年2月完成初始业务合并期间担任SPAC旗下Semper Paratus Acquisition Corporation（n/k/a Tevogen Bio Holdings Inc.（NASDAQ：TVGN））的董事。Fell先生于2023年8月至2025年2月完成初始业务合并之前，曾担任SPAC旗下PowerUp Acquisition Corp.（NASDAQ：PWUP）的董事。他目前是位于加利福尼亚州戴维斯的经济学教学基金会的教授和研究所所长，以及科罗拉多大学科罗拉多斯普林斯分校的经济学兼职教授。1995 – 2012年，Fell先生在南佛罗里达大学任职，担任执行MBA教员、执行和专业教育主任以及公共政策研究所高级研究员。他还曾担任法国拉罗谢尔大学经济学客座教授，同时担任伊利诺伊州立大学和俄亥俄州立大学经济学兼职教授。Fell先生拥有印第安纳州立大学的经济学本科和研究生学位，并且几乎是伊利诺伊州立大学的经济学学位论文（ABD）。通过与教授经济学基金会和科罗拉多大学科罗拉多斯普林斯分校的合作，他在44个州、遍布加拿大、群岛和东欧的经济政策和环境经济学研究生院进行了研究。
Donald G. Fell has served as an independent director of company since January 2014. Mr. Fell has also served as a director of Kernel Group Holdings, Inc. (NASDAQ: KRNL), a SPAC, since December 2022, served as a director of Oceantech Acquisitions I Corp. (NASDAQ: OTEC), a SPAC, since March 2023, and served as a director of Integrated Wellness Acquisition Corp (NYSE: WEL), a SPAC, since February 2024. Mr. Fell served as a director of Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc. (NASDAQ: OCEA)), a SPAC, from June 2021 until the completion of its initial business combination in February 2023. Mr. Fell served as a director of Semper Paratus Acquisition Corporation (n/k/a Tevogen Bio Holdings Inc. (NASDAQ: TVGN)), a SPAC, from June 2023 until the completion of its initial business combination in February 2024. Mr. Fell served as a director of PowerUp Acquisition Corp. (NASDAQ: PWUP), a SPAC, from August 2023 until the completion of its initial business combination in February 2025.He is presently Professor and Institute Director for the Davis, California based Foundation for Teaching Economics and adjunct professor of economics for the University of Colorado, Colorado, Springs. From 1995 – 2012, Mr. Fell held positions with the University of South Florida as a member of the Executive MBA faculty, Director of Executive and Professional Education, and Senior Fellow of the Public Policy Institute. He has also served as a visiting professor of economics at the University of LaRochelle, France, and as an adjunct professor of economics at both Illinois State University and The Ohio State University. Mr. Fell holds undergraduate and graduate degrees in economics from Indiana State University and is all but dissertation (ABD) in economics from Illinois State University. Through his work with the Foundation for Teaching Economics and the University of Colorado, Colorado Springs, he has conducted graduate institutes on economic policy and environmental economics in 44 states, throughout Canada, the Islands, and Eastern Europe. - Donald G. Fell自2014年1月起担任公司独立董事。Fell先生还曾担任SPAC的董事。Kernel Group Holdings, Inc.（纳斯达克股票代码：KRNL）自2022年12月起担任SPAC的董事。OceanTech Acquisitions I Corp.丨OTEC（纳斯达克股票代码：TERM3）自2023年3月起担任董事，以及SPAC的Integrated Wellness Acquisition Corp（纽约证券交易所股票代码：WEL）的董事，自2024年2月起担任。Fell先生于2021年6月至2023年2月完成初始业务合并期间，曾担任SPAC旗下Aesther Healthcare Acquisition Corp.（n/k/a Ocean Biomedical, Inc.（纳斯达克股票代码：TERM1））的董事。Fell先生于2023年6月至2024年2月完成初始业务合并期间担任SPAC旗下Semper Paratus Acquisition Corporation（n/k/a Tevogen Bio Holdings Inc.（NASDAQ：TVGN））的董事。Fell先生于2023年8月至2025年2月完成初始业务合并之前，曾担任SPAC旗下PowerUp Acquisition Corp.（NASDAQ：PWUP）的董事。他目前是位于加利福尼亚州戴维斯的经济学教学基金会的教授和研究所所长，以及科罗拉多大学科罗拉多斯普林斯分校的经济学兼职教授。1995 – 2012年，Fell先生在南佛罗里达大学任职，担任执行MBA教员、执行和专业教育主任以及公共政策研究所高级研究员。他还曾担任法国拉罗谢尔大学经济学客座教授，同时担任伊利诺伊州立大学和俄亥俄州立大学经济学兼职教授。Fell先生拥有印第安纳州立大学的经济学本科和研究生学位，并且几乎是伊利诺伊州立大学的经济学学位论文（ABD）。通过与教授经济学基金会和科罗拉多大学科罗拉多斯普林斯分校的合作，他在44个州、遍布加拿大、群岛和东欧的经济政策和环境经济学研究生院进行了研究。
- Donald G. Fell has served as an independent director of company since January 2014. Mr. Fell has also served as a director of Kernel Group Holdings, Inc. (NASDAQ: KRNL), a SPAC, since December 2022, served as a director of Oceantech Acquisitions I Corp. (NASDAQ: OTEC), a SPAC, since March 2023, and served as a director of Integrated Wellness Acquisition Corp (NYSE: WEL), a SPAC, since February 2024. Mr. Fell served as a director of Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc. (NASDAQ: OCEA)), a SPAC, from June 2021 until the completion of its initial business combination in February 2023. Mr. Fell served as a director of Semper Paratus Acquisition Corporation (n/k/a Tevogen Bio Holdings Inc. (NASDAQ: TVGN)), a SPAC, from June 2023 until the completion of its initial business combination in February 2024. Mr. Fell served as a director of PowerUp Acquisition Corp. (NASDAQ: PWUP), a SPAC, from August 2023 until the completion of its initial business combination in February 2025.He is presently Professor and Institute Director for the Davis, California based Foundation for Teaching Economics and adjunct professor of economics for the University of Colorado, Colorado, Springs. From 1995 – 2012, Mr. Fell held positions with the University of South Florida as a member of the Executive MBA faculty, Director of Executive and Professional Education, and Senior Fellow of the Public Policy Institute. He has also served as a visiting professor of economics at the University of LaRochelle, France, and as an adjunct professor of economics at both Illinois State University and The Ohio State University. Mr. Fell holds undergraduate and graduate degrees in economics from Indiana State University and is all but dissertation (ABD) in economics from Illinois State University. Through his work with the Foundation for Teaching Economics and the University of Colorado, Colorado Springs, he has conducted graduate institutes on economic policy and environmental economics in 44 states, throughout Canada, the Islands, and Eastern Europe.
- Mayur Doshi
-
Mayur Doshi是AlfaGene Bioscience，Inc.的总裁兼首席执行官。他成功发起了几家公司，过去十年一直担任Apogee Pharma的首席执行官。他还于2023年8月至2025年2月期间担任特殊目的收购公司PowerUp Acquisition Corp.（NASDAQ：PWUP）的董事。他在全球仿制药市场拥有超过20年的经验。他是一位训练有素的化学家和经验丰富的企业家，在活性药物成分方面拥有丰富的经验。拥有20多年制药和生物技术行业经验，1988年进入仿制药行业。他是Apogee Pharma，Inc.的董事长兼董事总经理，Apogee Pharma，Inc.是应用程序编程接口（API）的主要进口商。他也是一家仿制药公司的主要投资者，是AlfaGene的创始人和主要投资者。他在制药行业广泛工作和管理，创建了一家价值数百万美元的公司。Doshi先生还担任各种组织的慈善家。
Mayur Doshi is President and Chief Executive Officer of AlfaGene Bioscience, Inc. He has successfully initiated several companies and for the last ten years has been the Chief Executive Officer of Apogee Pharma. He also served as a director of PowerUp Acquisition Corp. (NASDAQ: PWUP), a special purpose acquisition company, from August 2023 to February 2025. He has over 20 years of experience in the global generic pharmaceutical market. He is a trained chemist and seasoned entrepreneur with extensive experience in active pharmaceutical ingredients. He has more than 20 years of pharmaceutical and bio tech industry experience, entering the generic pharmaceutical industry in 1988. He is Chairman and Managing Director of Apogee Pharma, Inc., a major importer of application programming interfaces (APIs). He is also a major investor in a generic pharmaceutical company and is the founder of, and primary investor in, AlfaGene. He worked and managed extensively in the pharmaceutical industry and created a multimillion dollar company. Mr. Doshi also serves as a philanthropist for various organizations. - Mayur Doshi是AlfaGene Bioscience，Inc.的总裁兼首席执行官。他成功发起了几家公司，过去十年一直担任Apogee Pharma的首席执行官。他还于2023年8月至2025年2月期间担任特殊目的收购公司PowerUp Acquisition Corp.（NASDAQ：PWUP）的董事。他在全球仿制药市场拥有超过20年的经验。他是一位训练有素的化学家和经验丰富的企业家，在活性药物成分方面拥有丰富的经验。拥有20多年制药和生物技术行业经验，1988年进入仿制药行业。他是Apogee Pharma，Inc.的董事长兼董事总经理，Apogee Pharma，Inc.是应用程序编程接口（API）的主要进口商。他也是一家仿制药公司的主要投资者，是AlfaGene的创始人和主要投资者。他在制药行业广泛工作和管理，创建了一家价值数百万美元的公司。Doshi先生还担任各种组织的慈善家。
- Mayur Doshi is President and Chief Executive Officer of AlfaGene Bioscience, Inc. He has successfully initiated several companies and for the last ten years has been the Chief Executive Officer of Apogee Pharma. He also served as a director of PowerUp Acquisition Corp. (NASDAQ: PWUP), a special purpose acquisition company, from August 2023 to February 2025. He has over 20 years of experience in the global generic pharmaceutical market. He is a trained chemist and seasoned entrepreneur with extensive experience in active pharmaceutical ingredients. He has more than 20 years of pharmaceutical and bio tech industry experience, entering the generic pharmaceutical industry in 1988. He is Chairman and Managing Director of Apogee Pharma, Inc., a major importer of application programming interfaces (APIs). He is also a major investor in a generic pharmaceutical company and is the founder of, and primary investor in, AlfaGene. He worked and managed extensively in the pharmaceutical industry and created a multimillion dollar company. Mr. Doshi also serves as a philanthropist for various organizations.
- Narasimhan Mani
-
Narasimhan Mani自2025年5月起担任董事兼联合首席执行官兼总裁。2026年5月至今担任临时首席财务官。Mani博士是一位经验丰富的医疗保健专业人士，在制药行业拥有超过25年的经验。在加入Scienture之前，他最近担任Kesin Pharma Corporation的总裁兼首席执行官，这是一家专注于将专业和品牌产品商业化的专业制药公司。他过去担任的职务包括担任仿制药和特种药产品公司Xiromed LLC的首席执行官，以及在Amneal制药担任全球企业战略和业务发展副总裁，在那里他领导了公司在全球战略、投资组合管理、业务发展和商业运营方面的所有战略计划。他之前的经历还包括在新泽西州新布朗斯威克的强生担任公司财务和战略规划负责人，负责制药和医疗器械领域的工作。他还曾在Forest Laboratories和Par Pharmaceuticals担任研究科学家和产品开发负责人。他是专注于生命科学的私募股权公司New Rhein Healthcare Investors的常驻高管受邀成员，并在他们投资组合公司之一的Corsair Pharma，Inc.担任董事会成员。Mani博士在制药和医疗领域的旅程始于他在印度Pilani的BITS获得的B.Pharm（荣誉），他于1995年完成了这项工作。他随后获得的研究生学位包括1998年获得俄克拉何马大学诺曼分校的分析化学硕士学位，2003年获得雅典乔治亚大学的药剂学博士学位，2008年获得纽约州纽约哥伦比亚商学院的金融和市场营销MBA学位。Mani博士也是2021年9月的2021年杰出50名亚裔美国人商业奖的获得者。
Narasimhan Mani has served as a director and Co Chief Executive Officer and President since May 2025. He has served as Interim Chief Financial Officer since May 2026. Dr. Mani is an experienced healthcare professional with over 25 years of experience in the pharmaceutical industry. Prior to Scienture, he most recently served as the President and Chief Executive Officer for Kesin Pharma Corporation, a specialty pharma company with a focus on commercializing specialty and brand products. His past roles include serving as the Chief Executive Officer of Xiromed LLC, a generics and specialty drug product company and as the Vice President, Global Corporate Strategy and Business Development, at Amneal Pharmaceuticals where he led all the company's strategic initiatives across Global Strategy, Portfolio Management, Business Development, and Commercial Operations. His previous experiences also include being the Corporate Finance and Strategic Planning Leader at Johnson & Johnson in New Brunswick, New Jersey, in the pharmaceutical and medical device sectors. He also worked as a Research Scientist and Product Development leader during his time at Forest Laboratories and Par Pharmaceuticals. He is an invited member of the Executives in Residence at New Rhein Healthcare Investors, a life sciences focused private equity firm, and serves on the board of directors at Corsair Pharma, Inc., one of their portfolio companies. Dr. Mani's journey in the pharmaceutical and healthcare space began with his B.Pharm (Hons.) from BITS, Pilani, India which he completed in 1995. His subsequent graduate degrees include M.S. Analytical Chemistry, from the University of Oklahoma, Norman in 1998, Ph.D. in Pharmaceutics, from the University of Georgia, Athens in 2003 and MBA in Finance and Marketing, from Columbia Business School, New York, NY in 2008. Dr. Mani is also the recipient of the 2021 Outstanding 50 Asian Americans in Business Award in September 2021. - Narasimhan Mani自2025年5月起担任董事兼联合首席执行官兼总裁。2026年5月至今担任临时首席财务官。Mani博士是一位经验丰富的医疗保健专业人士，在制药行业拥有超过25年的经验。在加入Scienture之前，他最近担任Kesin Pharma Corporation的总裁兼首席执行官，这是一家专注于将专业和品牌产品商业化的专业制药公司。他过去担任的职务包括担任仿制药和特种药产品公司Xiromed LLC的首席执行官，以及在Amneal制药担任全球企业战略和业务发展副总裁，在那里他领导了公司在全球战略、投资组合管理、业务发展和商业运营方面的所有战略计划。他之前的经历还包括在新泽西州新布朗斯威克的强生担任公司财务和战略规划负责人，负责制药和医疗器械领域的工作。他还曾在Forest Laboratories和Par Pharmaceuticals担任研究科学家和产品开发负责人。他是专注于生命科学的私募股权公司New Rhein Healthcare Investors的常驻高管受邀成员，并在他们投资组合公司之一的Corsair Pharma，Inc.担任董事会成员。Mani博士在制药和医疗领域的旅程始于他在印度Pilani的BITS获得的B.Pharm（荣誉），他于1995年完成了这项工作。他随后获得的研究生学位包括1998年获得俄克拉何马大学诺曼分校的分析化学硕士学位，2003年获得雅典乔治亚大学的药剂学博士学位，2008年获得纽约州纽约哥伦比亚商学院的金融和市场营销MBA学位。Mani博士也是2021年9月的2021年杰出50名亚裔美国人商业奖的获得者。
- Narasimhan Mani has served as a director and Co Chief Executive Officer and President since May 2025. He has served as Interim Chief Financial Officer since May 2026. Dr. Mani is an experienced healthcare professional with over 25 years of experience in the pharmaceutical industry. Prior to Scienture, he most recently served as the President and Chief Executive Officer for Kesin Pharma Corporation, a specialty pharma company with a focus on commercializing specialty and brand products. His past roles include serving as the Chief Executive Officer of Xiromed LLC, a generics and specialty drug product company and as the Vice President, Global Corporate Strategy and Business Development, at Amneal Pharmaceuticals where he led all the company's strategic initiatives across Global Strategy, Portfolio Management, Business Development, and Commercial Operations. His previous experiences also include being the Corporate Finance and Strategic Planning Leader at Johnson & Johnson in New Brunswick, New Jersey, in the pharmaceutical and medical device sectors. He also worked as a Research Scientist and Product Development leader during his time at Forest Laboratories and Par Pharmaceuticals. He is an invited member of the Executives in Residence at New Rhein Healthcare Investors, a life sciences focused private equity firm, and serves on the board of directors at Corsair Pharma, Inc., one of their portfolio companies. Dr. Mani's journey in the pharmaceutical and healthcare space began with his B.Pharm (Hons.) from BITS, Pilani, India which he completed in 1995. His subsequent graduate degrees include M.S. Analytical Chemistry, from the University of Oklahoma, Norman in 1998, Ph.D. in Pharmaceutics, from the University of Georgia, Athens in 2003 and MBA in Finance and Marketing, from Columbia Business School, New York, NY in 2008. Dr. Mani is also the recipient of the 2021 Outstanding 50 Asian Americans in Business Award in September 2021.
- Shankar Hariharan
-
Shankar Hariharan自2025年5月起担任董事会执行主席和联合首席执行官。Hariharan博士在成功领导品牌、专业和仿制药业务方面拥有超过39年的经验，曾在Scienture，LLC、Forest Labs、Par Pharmaceuticals和Amneal制药担任多个领导职务。他最近是Scienture的创始人、总裁和首席执行官。在Amneal担任执行副总裁兼首席科学官期间，他负责全球研发、全球监管事务和特种产品开发，并在公司实现高利润率的显着收入增长（> $ 1.5B）方面发挥了重要作用。在加入AmNeal之前，Hariharan博士创立了DermAct，这是一家专门从事皮肤科关键适应症的新分子发现和产品开发的研发机构，导致该公司成功收购。Hariharan博士在印度的Banaras印度教大学（BHU）获得药学学士学位，并在马萨诸塞州波士顿的东北大学获得药物科学博士学位。Hariharan博士目前在Depymed，Inc.董事会以及New Rhein Healthcare，LLC和MAA实验室的顾问委员会任职。
Shankar Hariharan has served as Executive Chairman of board of directors and Co Chief Executive Officer since May 2025. Dr. Hariharan has over 39 years of experience in successfully leading branded, specialty, and generic pharmaceutical businesses and has held several leadership positions at Scienture, LLC, Forest Labs, Par Pharmaceuticals, and Amneal Pharmaceuticals. He most recently was the founder, president, and chief executive officer of Scienture. At Amneal in his role as the Executive Vice President and Chief Scientific Officer, he oversaw Global Research & Development, Global Regulatory Affairs, and Specialty Product Development and was instrumental in the company achieving significant revenue growth (>$1.5B) with high profit margins. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in new molecule discovery and product development for key indications in Dermatology, leading to the company's successful acquisition. Dr. Hariharan obtained his bachelor's degree in pharmacy at the Banaras Hindu University (BHU) in India and his Ph.D. in Pharmaceutical Sciences at Northeastern University in Boston, Massachusetts. Dr. Hariharan currently serves on the board of Depymed, Inc. and on the advisory board of New Rhein Healthcare, LLC, and MAA Laboratories. - Shankar Hariharan自2025年5月起担任董事会执行主席和联合首席执行官。Hariharan博士在成功领导品牌、专业和仿制药业务方面拥有超过39年的经验，曾在Scienture，LLC、Forest Labs、Par Pharmaceuticals和Amneal制药担任多个领导职务。他最近是Scienture的创始人、总裁和首席执行官。在Amneal担任执行副总裁兼首席科学官期间，他负责全球研发、全球监管事务和特种产品开发，并在公司实现高利润率的显着收入增长（> $ 1.5B）方面发挥了重要作用。在加入AmNeal之前，Hariharan博士创立了DermAct，这是一家专门从事皮肤科关键适应症的新分子发现和产品开发的研发机构，导致该公司成功收购。Hariharan博士在印度的Banaras印度教大学（BHU）获得药学学士学位，并在马萨诸塞州波士顿的东北大学获得药物科学博士学位。Hariharan博士目前在Depymed，Inc.董事会以及New Rhein Healthcare，LLC和MAA实验室的顾问委员会任职。
- Shankar Hariharan has served as Executive Chairman of board of directors and Co Chief Executive Officer since May 2025. Dr. Hariharan has over 39 years of experience in successfully leading branded, specialty, and generic pharmaceutical businesses and has held several leadership positions at Scienture, LLC, Forest Labs, Par Pharmaceuticals, and Amneal Pharmaceuticals. He most recently was the founder, president, and chief executive officer of Scienture. At Amneal in his role as the Executive Vice President and Chief Scientific Officer, he oversaw Global Research & Development, Global Regulatory Affairs, and Specialty Product Development and was instrumental in the company achieving significant revenue growth (>$1.5B) with high profit margins. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in new molecule discovery and product development for key indications in Dermatology, leading to the company's successful acquisition. Dr. Hariharan obtained his bachelor's degree in pharmacy at the Banaras Hindu University (BHU) in India and his Ph.D. in Pharmaceutical Sciences at Northeastern University in Boston, Massachusetts. Dr. Hariharan currently serves on the board of Depymed, Inc. and on the advisory board of New Rhein Healthcare, LLC, and MAA Laboratories.
- Subbarao Jayanthi
-
Subbarao Jayanthi是Interlude Biopharma的联合创始人和董事会成员/CBO，Interlude Biopharma是一家GI公司，有三种晚期新型药物正在开发中，用于治疗胃肠道疾病。Jayanthi先生也是RXC International的创始人和管理合伙人，已经在该公司工作了十多年。RXC是一家战略咨询公司，为生物制药公司的增长战略提供建议。在该公司任职期间，Jayanthi先生曾就美国、欧盟和日本的公司战略、投资组合战略以及许可/并购交易向多家生物制药公司的高级管理人员和董事会成员提供建议。他还是Modig Life Sciences的高级顾问，Modig Life Sciences是一家罕见病公司，为一种致命的神经退行性疾病开发反义寡核苷酸。在此之前，Subbarao是全球生物制药20强公司Daiichi Sankyo的业务规划主管。在他职业生涯的早期，他曾在BCG等全球战略咨询公司担任领导职务。他撰写了有关生物制药商业化、价值链管理和投资的书籍。西北大学家乐氏管理学院战略、金融、市场营销MBA。
Subbarao Jayanthi is a co founder and Board Member/CBO of Interlude Biopharma, a GI company with three late stage novel medications under development for gastrointestinal disorders. Mr. Jayanthi is also the founder and Managing Partner of RxC International and has been with the company for more than a decade. RxC is a strategy consulting firm advising biopharma companies on growth strategies and while at the firm Mr. Jayanthi has advised senior executives and board members at several biopharma companies on corporate strategy, portfolio strategy, and licensing/M&A transactions in the US, EU, and Japan. He is also a Senior Advisor to Modig Life Sciences, a rare disease company developing an antisense oligonucleotide for a fatal neurodegenerative disease. Before this, Subbarao was the head of business planning at Daiichi Sankyo, a Top 20 global biopharma company. He held leadership positions at global strategy consulting firms such as BCG and others, earlier in his career. He has authored books on biopharma commercialization, value chain management, and investments. He has an MBA in strategy, finance, and marketing from Kellogg School of Management at Northwestern University. - Subbarao Jayanthi是Interlude Biopharma的联合创始人和董事会成员/CBO，Interlude Biopharma是一家GI公司，有三种晚期新型药物正在开发中，用于治疗胃肠道疾病。Jayanthi先生也是RXC International的创始人和管理合伙人，已经在该公司工作了十多年。RXC是一家战略咨询公司，为生物制药公司的增长战略提供建议。在该公司任职期间，Jayanthi先生曾就美国、欧盟和日本的公司战略、投资组合战略以及许可/并购交易向多家生物制药公司的高级管理人员和董事会成员提供建议。他还是Modig Life Sciences的高级顾问，Modig Life Sciences是一家罕见病公司，为一种致命的神经退行性疾病开发反义寡核苷酸。在此之前，Subbarao是全球生物制药20强公司Daiichi Sankyo的业务规划主管。在他职业生涯的早期，他曾在BCG等全球战略咨询公司担任领导职务。他撰写了有关生物制药商业化、价值链管理和投资的书籍。西北大学家乐氏管理学院战略、金融、市场营销MBA。
- Subbarao Jayanthi is a co founder and Board Member/CBO of Interlude Biopharma, a GI company with three late stage novel medications under development for gastrointestinal disorders. Mr. Jayanthi is also the founder and Managing Partner of RxC International and has been with the company for more than a decade. RxC is a strategy consulting firm advising biopharma companies on growth strategies and while at the firm Mr. Jayanthi has advised senior executives and board members at several biopharma companies on corporate strategy, portfolio strategy, and licensing/M&A transactions in the US, EU, and Japan. He is also a Senior Advisor to Modig Life Sciences, a rare disease company developing an antisense oligonucleotide for a fatal neurodegenerative disease. Before this, Subbarao was the head of business planning at Daiichi Sankyo, a Top 20 global biopharma company. He held leadership positions at global strategy consulting firms such as BCG and others, earlier in his career. He has authored books on biopharma commercialization, value chain management, and investments. He has an MBA in strategy, finance, and marketing from Kellogg School of Management at Northwestern University.
高管简历
中英对照 | 中文 | 英文- Narasimhan Mani
Narasimhan Mani自2025年5月起担任董事兼联合首席执行官兼总裁。2026年5月至今担任临时首席财务官。Mani博士是一位经验丰富的医疗保健专业人士，在制药行业拥有超过25年的经验。在加入Scienture之前，他最近担任Kesin Pharma Corporation的总裁兼首席执行官，这是一家专注于将专业和品牌产品商业化的专业制药公司。他过去担任的职务包括担任仿制药和特种药产品公司Xiromed LLC的首席执行官，以及在Amneal制药担任全球企业战略和业务发展副总裁，在那里他领导了公司在全球战略、投资组合管理、业务发展和商业运营方面的所有战略计划。他之前的经历还包括在新泽西州新布朗斯威克的强生担任公司财务和战略规划负责人，负责制药和医疗器械领域的工作。他还曾在Forest Laboratories和Par Pharmaceuticals担任研究科学家和产品开发负责人。他是专注于生命科学的私募股权公司New Rhein Healthcare Investors的常驻高管受邀成员，并在他们投资组合公司之一的Corsair Pharma，Inc.担任董事会成员。Mani博士在制药和医疗领域的旅程始于他在印度Pilani的BITS获得的B.Pharm（荣誉），他于1995年完成了这项工作。他随后获得的研究生学位包括1998年获得俄克拉何马大学诺曼分校的分析化学硕士学位，2003年获得雅典乔治亚大学的药剂学博士学位，2008年获得纽约州纽约哥伦比亚商学院的金融和市场营销MBA学位。Mani博士也是2021年9月的2021年杰出50名亚裔美国人商业奖的获得者。
Narasimhan Mani has served as a director and Co Chief Executive Officer and President since May 2025. He has served as Interim Chief Financial Officer since May 2026. Dr. Mani is an experienced healthcare professional with over 25 years of experience in the pharmaceutical industry. Prior to Scienture, he most recently served as the President and Chief Executive Officer for Kesin Pharma Corporation, a specialty pharma company with a focus on commercializing specialty and brand products. His past roles include serving as the Chief Executive Officer of Xiromed LLC, a generics and specialty drug product company and as the Vice President, Global Corporate Strategy and Business Development, at Amneal Pharmaceuticals where he led all the company's strategic initiatives across Global Strategy, Portfolio Management, Business Development, and Commercial Operations. His previous experiences also include being the Corporate Finance and Strategic Planning Leader at Johnson & Johnson in New Brunswick, New Jersey, in the pharmaceutical and medical device sectors. He also worked as a Research Scientist and Product Development leader during his time at Forest Laboratories and Par Pharmaceuticals. He is an invited member of the Executives in Residence at New Rhein Healthcare Investors, a life sciences focused private equity firm, and serves on the board of directors at Corsair Pharma, Inc., one of their portfolio companies. Dr. Mani's journey in the pharmaceutical and healthcare space began with his B.Pharm (Hons.) from BITS, Pilani, India which he completed in 1995. His subsequent graduate degrees include M.S. Analytical Chemistry, from the University of Oklahoma, Norman in 1998, Ph.D. in Pharmaceutics, from the University of Georgia, Athens in 2003 and MBA in Finance and Marketing, from Columbia Business School, New York, NY in 2008. Dr. Mani is also the recipient of the 2021 Outstanding 50 Asian Americans in Business Award in September 2021.- Narasimhan Mani自2025年5月起担任董事兼联合首席执行官兼总裁。2026年5月至今担任临时首席财务官。Mani博士是一位经验丰富的医疗保健专业人士，在制药行业拥有超过25年的经验。在加入Scienture之前，他最近担任Kesin Pharma Corporation的总裁兼首席执行官，这是一家专注于将专业和品牌产品商业化的专业制药公司。他过去担任的职务包括担任仿制药和特种药产品公司Xiromed LLC的首席执行官，以及在Amneal制药担任全球企业战略和业务发展副总裁，在那里他领导了公司在全球战略、投资组合管理、业务发展和商业运营方面的所有战略计划。他之前的经历还包括在新泽西州新布朗斯威克的强生担任公司财务和战略规划负责人，负责制药和医疗器械领域的工作。他还曾在Forest Laboratories和Par Pharmaceuticals担任研究科学家和产品开发负责人。他是专注于生命科学的私募股权公司New Rhein Healthcare Investors的常驻高管受邀成员，并在他们投资组合公司之一的Corsair Pharma，Inc.担任董事会成员。Mani博士在制药和医疗领域的旅程始于他在印度Pilani的BITS获得的B.Pharm（荣誉），他于1995年完成了这项工作。他随后获得的研究生学位包括1998年获得俄克拉何马大学诺曼分校的分析化学硕士学位，2003年获得雅典乔治亚大学的药剂学博士学位，2008年获得纽约州纽约哥伦比亚商学院的金融和市场营销MBA学位。Mani博士也是2021年9月的2021年杰出50名亚裔美国人商业奖的获得者。
- Narasimhan Mani has served as a director and Co Chief Executive Officer and President since May 2025. He has served as Interim Chief Financial Officer since May 2026. Dr. Mani is an experienced healthcare professional with over 25 years of experience in the pharmaceutical industry. Prior to Scienture, he most recently served as the President and Chief Executive Officer for Kesin Pharma Corporation, a specialty pharma company with a focus on commercializing specialty and brand products. His past roles include serving as the Chief Executive Officer of Xiromed LLC, a generics and specialty drug product company and as the Vice President, Global Corporate Strategy and Business Development, at Amneal Pharmaceuticals where he led all the company's strategic initiatives across Global Strategy, Portfolio Management, Business Development, and Commercial Operations. His previous experiences also include being the Corporate Finance and Strategic Planning Leader at Johnson & Johnson in New Brunswick, New Jersey, in the pharmaceutical and medical device sectors. He also worked as a Research Scientist and Product Development leader during his time at Forest Laboratories and Par Pharmaceuticals. He is an invited member of the Executives in Residence at New Rhein Healthcare Investors, a life sciences focused private equity firm, and serves on the board of directors at Corsair Pharma, Inc., one of their portfolio companies. Dr. Mani's journey in the pharmaceutical and healthcare space began with his B.Pharm (Hons.) from BITS, Pilani, India which he completed in 1995. His subsequent graduate degrees include M.S. Analytical Chemistry, from the University of Oklahoma, Norman in 1998, Ph.D. in Pharmaceutics, from the University of Georgia, Athens in 2003 and MBA in Finance and Marketing, from Columbia Business School, New York, NY in 2008. Dr. Mani is also the recipient of the 2021 Outstanding 50 Asian Americans in Business Award in September 2021.
- Shankar Hariharan
Shankar Hariharan自2025年5月起担任董事会执行主席和联合首席执行官。Hariharan博士在成功领导品牌、专业和仿制药业务方面拥有超过39年的经验，曾在Scienture，LLC、Forest Labs、Par Pharmaceuticals和Amneal制药担任多个领导职务。他最近是Scienture的创始人、总裁和首席执行官。在Amneal担任执行副总裁兼首席科学官期间，他负责全球研发、全球监管事务和特种产品开发，并在公司实现高利润率的显着收入增长（> $ 1.5B）方面发挥了重要作用。在加入AmNeal之前，Hariharan博士创立了DermAct，这是一家专门从事皮肤科关键适应症的新分子发现和产品开发的研发机构，导致该公司成功收购。Hariharan博士在印度的Banaras印度教大学（BHU）获得药学学士学位，并在马萨诸塞州波士顿的东北大学获得药物科学博士学位。Hariharan博士目前在Depymed，Inc.董事会以及New Rhein Healthcare，LLC和MAA实验室的顾问委员会任职。
Shankar Hariharan has served as Executive Chairman of board of directors and Co Chief Executive Officer since May 2025. Dr. Hariharan has over 39 years of experience in successfully leading branded, specialty, and generic pharmaceutical businesses and has held several leadership positions at Scienture, LLC, Forest Labs, Par Pharmaceuticals, and Amneal Pharmaceuticals. He most recently was the founder, president, and chief executive officer of Scienture. At Amneal in his role as the Executive Vice President and Chief Scientific Officer, he oversaw Global Research & Development, Global Regulatory Affairs, and Specialty Product Development and was instrumental in the company achieving significant revenue growth (>$1.5B) with high profit margins. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in new molecule discovery and product development for key indications in Dermatology, leading to the company's successful acquisition. Dr. Hariharan obtained his bachelor's degree in pharmacy at the Banaras Hindu University (BHU) in India and his Ph.D. in Pharmaceutical Sciences at Northeastern University in Boston, Massachusetts. Dr. Hariharan currently serves on the board of Depymed, Inc. and on the advisory board of New Rhein Healthcare, LLC, and MAA Laboratories.- Shankar Hariharan自2025年5月起担任董事会执行主席和联合首席执行官。Hariharan博士在成功领导品牌、专业和仿制药业务方面拥有超过39年的经验，曾在Scienture，LLC、Forest Labs、Par Pharmaceuticals和Amneal制药担任多个领导职务。他最近是Scienture的创始人、总裁和首席执行官。在Amneal担任执行副总裁兼首席科学官期间，他负责全球研发、全球监管事务和特种产品开发，并在公司实现高利润率的显着收入增长（> $ 1.5B）方面发挥了重要作用。在加入AmNeal之前，Hariharan博士创立了DermAct，这是一家专门从事皮肤科关键适应症的新分子发现和产品开发的研发机构，导致该公司成功收购。Hariharan博士在印度的Banaras印度教大学（BHU）获得药学学士学位，并在马萨诸塞州波士顿的东北大学获得药物科学博士学位。Hariharan博士目前在Depymed，Inc.董事会以及New Rhein Healthcare，LLC和MAA实验室的顾问委员会任职。
- Shankar Hariharan has served as Executive Chairman of board of directors and Co Chief Executive Officer since May 2025. Dr. Hariharan has over 39 years of experience in successfully leading branded, specialty, and generic pharmaceutical businesses and has held several leadership positions at Scienture, LLC, Forest Labs, Par Pharmaceuticals, and Amneal Pharmaceuticals. He most recently was the founder, president, and chief executive officer of Scienture. At Amneal in his role as the Executive Vice President and Chief Scientific Officer, he oversaw Global Research & Development, Global Regulatory Affairs, and Specialty Product Development and was instrumental in the company achieving significant revenue growth (>$1.5B) with high profit margins. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in new molecule discovery and product development for key indications in Dermatology, leading to the company's successful acquisition. Dr. Hariharan obtained his bachelor's degree in pharmacy at the Banaras Hindu University (BHU) in India and his Ph.D. in Pharmaceutical Sciences at Northeastern University in Boston, Massachusetts. Dr. Hariharan currently serves on the board of Depymed, Inc. and on the advisory board of New Rhein Healthcare, LLC, and MAA Laboratories.